Evidence map›Paper›PMID 35801703›Full record

ArticleAnnals of surgery2023

The Long-term Value of Bariatric Surgery Interventions for American Adults With Type 2 Diabetes Mellitus.

Ritika Chaturvedi, Tadeja Gracner, Bryan Tysinger, Kimberly Narain, Dana Goldman, Roland Sturm

Open access · greenAbstract read
In one paragraph

Article in Annals of surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ritika ChaturvediRAND Corporation, Santa Monica, CA.
Tadeja GracnerRAND Corporation, Santa Monica, CA.
Bryan TysingerLeonard D. Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, CA.
Kimberly NarainLeonard D. Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, CA.
Dana GoldmanLeonard D. Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, CA.
Roland SturmRAND Corporation, Santa Monica, CA.
RAND Corporation · USUniversity of Southern California · USUniversity of California, Los Angeles · US

Funding

Microsimulation of Obesity PoliciesR01HD087257 · NICHD · RAND CORPORATION · PI STURM, ROLAND · 2016 to 2020
$2.8M
NICHD NIH HHS R01 HD087257
6 · The paper itself

Abstract

backgroundBariatric surgery can cause type 2 diabetes (diabetes) remission for individuals with comorbid obesity, yet utilization is <1%. Surgery eligibility is currently limited to body mass index (BMI) ≥35 kg/m 2 , though the American Diabetes Association recommends expansion to BMI ≥30 kg/m 2 .

objectiveWe estimate the individual-level net social value benefits of diabetes remission through bariatric surgery and compare the population-level effects of expanding eligibility alone versus improving utilization for currently eligible individuals.

methodsUsing microsimulation, we quantified the net social value (difference in lifetime health/economic benefits and costs) of bariatric surgery-related diabetes remission for Americans with obesity and diabetes. We compared projected lifetime surgical outcomes to conventional management at individual and population levels for current utilization (1%) and eligibility (BMI ≥35 kg/m 2 ) and expansions of both (>1%, and BMI ≥30 kg/m 2 ).

resultsThe per capita net social value of bariatric surgery-related diabetes remission was $264,670 (95% confidence interval: $234,527-294,814) under current and $227,114 (95% confidence interval: $205,300-248,928) under expanded eligibility, an 11.1% and 9.16% improvement over conventional management. Quality-adjusted life expectancy represented the largest gains (current: $194,706; expanded: $169,002); followed by earnings ($51,395 and $46,466), and medical savings ($41,769 and $34,866) balanced against the surgery cost ($23,200). Doubling surgical utilization for currently eligible patients provides higher population gains ($34.9B) than only expanding eligibility at current utilization ($29.0B).

conclusionsDiabetes remission following bariatric surgery improves healthy life expectancy and provides net social benefit despite high procedural costs. Per capita benefits appear greater among currently eligible individuals. Therefore, policies that increase utilization may produce larger societal value than expanding eligibility criteria alone.

Indexed as

Bariatric SurgeryDiabetes Mellitus, Type 2Obesity, MorbidAdultBody Mass IndexComorbidityCost-Benefit AnalysisHumansObesity

Identifiers

PMID35801703
PMCPMC9825684
OpenAlexW4284963481

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.